House & Home
Tue, June 30, 2009Mon, June 29, 2009Sun, June 28, 2009Fri, June 26, 2009Thu, June 25, 2009Wed, June 24, 2009Tue, June 23, 2009Mon, June 22, 2009Fri, June 19, 2009Thu, June 18, 2009Wed, June 17, 2009Tue, June 16, 2009Mon, June 15, 2009Sun, June 14, 2009Fri, June 12, 2009Thu, June 11, 2009Wed, June 10, 2009Tue, June 9, 2009Mon, June 8, 2009Sun, June 7, 2009Fri, June 5, 2009Thu, June 4, 2009Wed, June 3, 2009Tue, June 2, 2009Mon, June 1, 2009Fri, May 29, 2009Thu, May 28, 2009Wed, May 27, 2009Tue, May 26, 2009Mon, May 25, 2009Fri, May 22, 2009Thu, May 21, 2009Wed, May 20, 2009Tue, May 19, 2009Mon, May 18, 2009Sun, May 17, 2009Fri, May 15, 2009Thu, May 14, 2009Wed, May 13, 2009Tue, May 12, 2009Mon, May 11, 2009Fri, May 8, 2009Thu, May 7, 2009Fri, May 1, 2009Thu, April 16, 2009Wed, April 15, 2009Tue, April 14, 2009Mon, April 13, 2009Thu, April 9, 2009Wed, April 8, 2009Tue, April 7, 2009Mon, April 6, 2009Fri, April 3, 2009Thu, April 2, 2009Wed, April 1, 2009Tue, March 31, 2009Mon, March 30, 2009Fri, March 27, 2009Thu, March 26, 2009Wed, March 25, 2009Tue, March 24, 2009Mon, March 23, 2009Fri, March 20, 2009Thu, March 19, 2009Wed, March 18, 2009Tue, March 17, 2009Mon, March 16, 2009Fri, March 13, 2009Thu, March 12, 2009Wed, March 11, 2009Critical Outcome Technologies Inc.: COTI-2 in Combination With Taxol(R) (Paclitaxel) Is Superior to Treatment With Paclitaxel A
//house-home.news-articles.net/content/2009/05/1 .. -is-superior-to-treatment-with-paclitaxel-a.html
Published in House and Home on Thursday, May 14th 2009 at 7:00 GMT, Last Modified on 2009-05-14 07:01:45 by Market WireLONDON, ONTARIO--(Marketwire - May 14, 2009) - Critical Outcome Technologies Inc. (TSX VENTURE:COT), announced positive results today from animal experiments carried out at a prominent American cancer research facility. The following results provide strong supportive evidence for the continued evaluation of COTI-2 in combination with conventional first line single agent therapy for the treatment of endometrial cancer:
- Up to 40% complete tumor regression (weight equals 0 mg) was observed in the combination treatment groups (paclitaxel plus COTI-2) while no complete regressions (0%) occurred in the paclitaxel alone treatment group.
- The combination treatment with paclitaxel plus COTI-2 was associated with a statistically significant improvement in absolute survival compared with the paclitaxel group.
- The tumor growth inhibition was 71.5% greater in the paclitaxel plus COTI-2 treated animals compared with paclitaxel alone.
- Combination treatments were well tolerated.
"We are delighted to see that intravenous COTI-2 in combination with paclitaxel showed superior treatment results compared to paclitaxel alone as measured by an improved tumor regression rate, an improved survival rate and delayed tumor growth in an animal model of aggressive human endometrial cancer (AN3-CA). These results are significant as they add to the impressive data set of COTI-2, showing efficacy against multiple cancers and low toxicity," said Dr. Wayne Danter, President and Chief Scientific Officer (CSO) of Critical Outcome Technologies Inc. (COTI).
COTI will present this new data to parties who have expressed interest in a commercial partnership related to COTI-2, including executives from several major pharmaceutical organizations, at BIO taking place May 18-21, 2009 in Atlanta, GA. "This new data will stimulate further discussions as we continue to evaluate our options pertaining to a licensing arrangement for COTI-2," said Mr. Michael Cloutier, Chief Executive Officer (CEO) of COTI. COTI will be represented at BIO by Mr. Michael Cloutier, CEO, Dr. Wayne Danter, President and CSO and Mr. Michael Barr, Director of Business Development and Marketing.
About Critical Outcome Technologies Inc. (COTI)
COTI is formed around a unique computational platform technology called CHEMSAS®, which allows for the accelerated identification, profiling and optimization of targeted small molecules potentially effective in the treatment of human diseases for which current therapy is either lacking or ineffective. COTI's business is focused on the discovery and preclinical development of libraries of novel, optimized lead molecules for the treatment of specific cancers, HIV and multiple sclerosis. Currently, five targeted libraries of lead compounds are under active development: small cell lung cancer, HIV integrase inhibitors, acute adult leukemia, multiple sclerosis and colorectal cancer.
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.
